Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03344965 | Olaparib In Metastatic Breast Cancer | active not recruiting | Phase 2 | 114 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03921684 | Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | active not recruiting | Phase 2 | 29 | Baruch BrennerOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03961672 |
| Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| active not recruiting |
| Phase 2 |
| 15 |
| City of Hope Medical CenterOTHER |
| 1 |
| Jan 5, 2026 |
| clinicaltrials |
| NCT03983993 | Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer(NIPAVect) | active not recruiting | Phase 2 | 26 | Emory UniversityOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05023967 | Metformin and Nightly Fasting in Women With Early Breast Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT05199051 | A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML(AGORA-1) | active not recruiting | Phase 2 | 19 | Centre Antoine LacassagneOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03090165 | Ribociclib and Bicalutamide in AR+ TNBC | active not recruiting | Phase 1 / Phase 2 | 37 | Kari WisinskiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03393845 | Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients | active not recruiting | Phase 2 | 47 | Nancy Chan, MDOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04762979 | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | active not recruiting | Phase 2 | 44 | Marina N SharifiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04959500 | Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05952037 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 114 | BeOne MedicinesINDUSTRY | 9 | Jan 2, 2026 | clinicaltrials |
| NCT06416696 | Toripalimab for High-risk Locally Advanced Cervical Cancer | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05858229 | Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. | active not recruiting | Phase 1 / Phase 2 | 12 | Sherrif IbrahimOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03809000 | A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery(STEEL) | active not recruiting | Phase 2 | 188 | RTOG Foundation, Inc.OTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT04604067 | Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. | active not recruiting | Phase 2 | 260 | Swiss Cancer InstituteOTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT05704049 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma(IZALCO) | active not recruiting | Phase 2 | 118 | SanofiINDUSTRY | 7 | Dec 29, 2025 | clinicaltrials |
| NCT03734809 | NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer | active not recruiting | Phase 2 | 43 | Chinese University of Hong KongOTHER | 2 | Dec 24, 2025 | clinicaltrials |
| NCT03991962 | Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma | active not recruiting | Phase 2 | 28 | Yale UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05130827 | Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | active not recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05503251 | Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases | active not recruiting | Phase 2 | 110 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03600233 | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | active not recruiting | Phase 2 | 34 | TaiRx, Inc.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03673124 | Ribociclib and Letrozole Treatment in Ovarian Cancer | active not recruiting | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04655365 | Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.(PROSTEP-002) | active not recruiting | Phase 2 | 50 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05305365 | Study Assessing QBS72S For Treating Brain Metastases | active not recruiting | Phase 2 | 21 | Stanford UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT02638090 | Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 120 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT03285412 | CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer(LEADER) | active not recruiting | Phase 2 | 120 | Massachusetts General HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04116411 | A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients(VIGAS2) | active not recruiting | Phase 2 | 220 | Cecilia Soderberg-NauclerOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT02452008 | Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03753334 | Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.(RCT-EPAII-BCR) | active not recruiting | Phase 2 | 39 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04079166 | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) | active not recruiting | Phase 2 | 173 | Scancell LtdINDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04691960 | A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging | active not recruiting | Phase 2 | 18 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05499013 | Study to Assess SLN124 in Patients With Polycythemia Vera(SLN) | active not recruiting | Phase 1 / Phase 2 | 69 | Silence Therapeutics plcINDUSTRY | 9 | Dec 19, 2025 | clinicaltrials |
| NCT03079999 | Study of Aspirin in Patients With Vestibular Schwannoma | active not recruiting | Phase 2 | 97 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03654768 | Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia | active not recruiting | Phase 2 | 81 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04009109 | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | active not recruiting | Phase 2 | 79 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05801939 | Cevostamab Following CAR T Cell Therapy for RRMM | active not recruiting | Phase 2 | 30 | University of PennsylvaniaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05902533 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation(REDEL) | active not recruiting | Phase 2 / Phase 3 | 33 | University of CincinnatiOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04863885 | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients | active not recruiting | Phase 1 / Phase 2 | 46 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05566574 | A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer | active not recruiting | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients(RAMP201J) | active not recruiting | Phase 2 | 16 | Verastem, Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05296512 | Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer | active not recruiting | Phase 2 | 30 | Elizabeth K. Lee MDOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02755896 | Trial to Compare Radiation Fibrosis With Five Versus Three Fractions | active not recruiting | Phase 2 | 350 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04025372 | INTREPId (INTermediate Risk Erection PreservatIon Trial) | active not recruiting | Phase 2 | 234 | Brigham and Women's HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04390399 | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 328 | ImmunityBio, Inc.INDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05410418 | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | active not recruiting | Phase 2 | 34 | Washington University School of MedicineOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05340270 | PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma(NeoTurbo) | active not recruiting | Phase 2 | 150 | Guangxi Medical UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02374242 | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases(ABC) | active not recruiting | Phase 2 | 76 | Melanoma Institute AustraliaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 5, 2026source: clinicaltrials